Homology Medicines Inc
(NAS:FIXX)
$
0.9347
0.0071 (0.77%)
Market Cap: 3.02 Mil
Enterprise Value: -78.32 Mil
PE Ratio: 0
PB Ratio: 0.04
GF Score: 32/100 Homology Medicines Inc at Bank of America NAPA Healthcare Conference Transcript
Jun 15, 2021 / 04:30PM GMT
Release Date Price:
$132.3
(-0.54%)
Jason Eron Zemansky
BofA Securities, Research Division - VP
Good afternoon, and welcome to our second day of our Napa virtual biopharma conference. My name is Jason Zemansky, and I'm an associate on Geoff Meacham's team. I'm very pleased this afternoon to introduce Arthur Tzianabos, the CEO of Homology Medicines, who's going to walk us through his very impressive and unique AAVHSC platform. Arthur, are you there?
Arthur O. Tzianabos
Homology Medicines, Inc. - President, CEO & Director
I am here. Hello, Jason, how are you?
Jason Eron Zemansky
BofA Securities, Research Division - VP
Doing well, thanks. And thanks for joining us. Well, look, let's, I think, jump right into questions.
Questions & Answers
Jason Eron Zemansky
BofA Securities, Research Division - VP
I think, obviously, for most investors, the biggest catalyst that's upcoming is the HMI-102, your gene therapy for adolescent and adult PKU Phase II. Top of mind for many, are we still on track for
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot